Specified Bulk Drugs Attract 5% GST Rate Rules AP AAR
The Andhra Pradesh AAR ruled that specified bulk drugs qualify for a reduced 5% GST rate instead of 18%.
- Ruling
- Order No. AAR/AP/03(GST)/2018 dated 28.03.2018
- Dated
- 28 Mar 2018
- Authority
- Authority for Advance Ruling
This page was written by Patron Accounting’s AI from the official release and reviewed before publishing. It explains the document in plain language. It is not the document itself. Where this page and the original differ, the original governs.
The short version
- Laurus Labs asked if specified bulk drugs attract 5% or 18% GST.
- Products included bulk Efavirenz, Emtricitabine, Suntinib Malate, Raltegravir, and Latanoprost.
- AAR ruled that listed bulk drugs qualify for the 5% GST rate.
- Specific drug listings override general chemical classifications attracting higher tax.
In short
Pharmaceutical manufacturer Laurus Labs asked the Andhra Pradesh Authority for Advance Ruling (AAR) about the GST rate on bulk drugs like Efavirenz and Emtricitabine. The firm wanted to know if these items qualify for a concessional 5% Goods and Services Tax (GST) rate under List 1 of Schedule I. Tax officers often classified such bulk ingredients as general organic chemicals, which carry an 18% GST rate under Schedule III. Laurus Labs argued that because these items are named specifically in the drug list, they should get the lower tax rate.
What has changed
How it worked before
Before order AAR/AP/03(GST)/2018, tax offices frequently treated bulk active pharmaceutical ingredients as raw organic chemicals taxable at 18% GST. Businesses were unsure whether the 5% GST rate applied only to finished tablets and syrups or extended to raw bulk forms as well.
What has changed
The Authority for Advance Ruling decided that specific entries in tax notifications override general chemical categories. Since the tax law uses the word 'drug' without limiting it to finished medicines, the lower 5% GST rate applies to bulk drugs named in List 1. This decision clarifies that listed active pharmaceutical ingredients qualify for the reduced tax rate.
Who this affects
Pharmaceutical manufacturers, chemical suppliers, and active pharmaceutical ingredient (API) makers selling raw drug components in India.
An example
An Andhra Pradesh chemical firm manufactures bulk Raltegravir Potassium to sell to medicine makers. Their local tax officer insists on collecting 18% GST, classifying the supply as an organic chemical. The manufacturer refers to ruling AAR/AP/03(GST)/2018, where the tax authority held that bulk Raltegravir Potassium falls under List 1 and attracts only 5% GST. The manufacturer can present this reasoning when applying for their own advance ruling to legally secure the 5% rate.
What you should do
Check if the specific bulk drugs or active pharmaceutical ingredients you manufacture are listed by name in List 1 of Schedule I under GST. Note that an advance ruling legally binds only the company that applied for it and its tax office. If your tax officer insists on an 18% tax rate, you should seek a separate advance ruling or consult a professional tax advisor before changing your tax rate.
If you do nothing
If a business unilaterally lowers its tax rate to 5% GST based on someone else's advance ruling, a tax officer can issue a demand notice for the 13% tax shortage. The company would have to pay the unpaid tax balance along with heavy interest and penalties. An advance ruling given to another company cannot be used as a legal defense during your own tax audit.
The terms explained
- Bulk drug
- An active chemical substance used to manufacture finished medicines, also called an active pharmaceutical ingredient.
- Input tax credit
- The GST a business pays on raw materials and services, which it can set off against the GST it collects on sales.
- Advance ruling
- An official written clarification issued by tax authorities to a specific applicant on how GST applies to their business transaction.
The ruling in detail
Authority for Advance Ruling
M/s Laurus Labs Limited
Order No. AAR/AP/03(GST)/2018 dated 28.03.2018 · Andhra Pradesh
Questions before the authority
- Whether the applicant is eligible to claim the benefit of lower rate of GST i.e., 5% under Sl. No. 180 of Schedule-I of the rate schedule under Notification No. 01/2017- Central Tax(Rate) dated 28.06.2017 read with the corrigendum dated 30.06.2017 on supply of 1. EFAVIRENZ, EMTRICITABINE, SUNTINIB MALATE, RALTEGRAVIR POTASIUM, LATANOPROST, which also falls under Sl. No. 40 of Schedule III.
Facts
The applicant is engaged in the manufacturing of pharmaceutical products, specifically bulk drugs and intermediates. They manufacture products including Efavirenz, Emtricitabine, Suntinib Malate, Raltegravir Potassium, and Latanoprost. A question arose whether these bulk drugs are eligible for the concessional GST rate of 5% applicable to specified drugs under Schedule I or if they attract 18% GST as organic chemicals under Schedule III.
Ruling
| Question | What the authority ruled |
|---|---|
| Supply of Efavirenz, Emtricitabine, Suntinib Malate, Raltegravir Potassium, and Latanoprost | Eligible for 5% GST under Sl. No. 180 of Schedule-I of Notification No. 01/2017-Central Tax (Rate) Applies to bulk drugs covered under List 1 appended to Schedule I |
The Authority held that the applicant is eligible to claim the lower GST rate of 5% under Sl. No. 180 of Schedule-I of Notification No. 01/2017-Central Tax (Rate) read with corrigendum dated 30.06.2017. The Authority ruled that the **specific entry overrides the general entry**, thereby entitling the specified bulk drugs to the lower rate.
Reasoning
The Authority observed that the specified items are explicitly listed under List 1 appended to Schedule I (Sl. No. 180) of Notification No. 01/2017-Central Tax (Rate). The word 'drug' in the entry is not restricted by terms like 'formulation' or 'bulk', thereby covering bulk drugs as well. Applying the principle that a **specific entry overrides the general entry**, the specific listing under List 1 of Schedule I prevails over the general classification of organic chemicals under Sl. No. 40 of Schedule III.
Provisions relied on
- Sl. No. 180 of Schedule-I to Notification No. 01/2017-Central Tax (Rate) dated 28.06.2017
- Corrigendum dated 30.06.2017 to Notification No. 01/2017-Central Tax (Rate)
- List 1 appended to Schedule-I of Notification No. 01/2017-Central Tax (Rate)
- Sl. No. 40 of Schedule-III to Notification No. 01/2017-Central Tax (Rate)
For the practitioner
This ruling establishes that bulk drugs enumerated in List 1 of Schedule I qualify for the **concessional GST rate of 5%**, even if they are active pharmaceutical ingredients classifiable under Chapter 29. It settled that the entry for 'drugs or medicines' is broad enough to cover bulk forms unless explicitly excluded.
Source
This is a summary prepared from the published order, which is a scanned document. It is a reading aid and not the authority: where the two differ, the order governs. Verify every provision against the original before relying on it.
Original order: https://www.gstcouncil.gov.in/sites/default/files/AAR/ap_03-2018_28-03-18_laurus_labs.pdf
Legibility of the scan, as read: high.
Prepared 16-10-2026.
About Patron Accounting LLP
Patron Accounting LLP is a CA and CS-led accounting and compliance firm that has been working with businesses across India since 2019. We handle the work that keeps a company correct with every department it answers to: day-to-day bookkeeping and accounting, GST registration and returns, income tax filing and assessments, TDS, payroll and PF/ESI, company and LLP incorporation, ROC and MCA compliance, statutory and internal audit, physical stock and inventory audits, trademark and other registrations, and the certificates and reports that banks, buyers and regulators ask for.
Our clients range from a first proprietorship registering for GST to established companies running operations across several states. Much of our work is exactly this: reading what a department has published and telling a business, in plain terms, whether it changes anything for them.
We operate from five offices and serve clients across the rest of India remotely:
- Pune (HQ): RTC Silver, B4-708, Sai Satyam Park, Wagholi, Pune, Maharashtra 412207
- Mumbai: 104, Rajshila Building, 597 J.S.S. Road, Marine Lines, Mumbai 400002
- Delhi: 3rd Floor, B-6/154-155, Sector 5, Rohini, Delhi 110085
- Gurugram: Pioneer Urban Square, B109, Golf Course Ext Road, Sector 62, Gurugram 122098
- Ahmedabad: Phoenix Tower, 1107, near Commerce Six Road, Drive In Road, Navrangpura, Ahmedabad, Gujarat 380009
If anything on this page affects you and you would like somebody to look at your own position, we are glad to help. Call +91 94594 56700, write to sales@patronaccounting.com, or visit patronaccounting.com. The first conversation costs nothing.